Relationship Between nm23 Expression and Clinical Factors in AML
| Clinical Factor (no.) . | nm23-H1 Index . | P . | nm23-H2 Index . | P . |
|---|---|---|---|---|
| Age (yr) | ||||
| ≤50 (53) | 101 ± 171 | 95 ± 119 | ||
| >50 (57) | 112 ± 123 | .275 | 95 ± 101 | .862 |
| Sex | ||||
| M (68) | 102 ± 87 | 89 ± 58 | ||
| F (42) | 115 ± 212 | .107 | 104 ± 162 | .216 |
| WBC (×109/L) | ||||
| ≤50 (79) | 103 ± 153 | 85 ± 102 | ||
| >50 (29) | 121 ± 136 | .266 | 119 ± 130 | .079 |
| LDH | ||||
| ≥N, ≤5 × N (92) | 96 ± 142 | 84 ± 96 | ||
| >5 × N (14) | 188 ± 179 | .006* | 159 ± 175 | .038* |
| CD7 | ||||
| Negative (70) | 105 ± 115 | 87 ± 94 | ||
| Positive (17) | 188 ± 279 | .019* | 141 ± 193 | .121 |
| Chromosomal aberration | ||||
| − (42) | 97 ± 80 | 85 ± 53 | ||
| + (65) | 116 ± 180 | .398 | 100 ± 136 | .438 |
| − (42) | 97 ± 80 | 85 ± 53 | ||
| t(8;21) (13) | 113 ± 108 | .898 | 79 ± 60 | .677 |
| t(15;17) (17) | 51 ± 29 | .010* | 63 ± 52 | .045* |
| inv(16) (3) | 78 ± 21 | .891 | 89 ± 43 | .733 |
| 11q23 (3) | 81 ± 66 | >.999 | 77 ± 44 | >.999 |
| MAKA (6) | 300 ± 471 | .554 | 213 ± 317 | .513 |
| others (25) | 122 ± 148 | .866 | 112 ± 28 | .856 |
| Response to initial chemotherapy | ||||
| CR (68) | 97 ± 115 | 91 ± 96 | ||
| NR (32) | 144 ± 212 | .020* | 110 ± 147 | .597 |
| Clinical Factor (no.) . | nm23-H1 Index . | P . | nm23-H2 Index . | P . |
|---|---|---|---|---|
| Age (yr) | ||||
| ≤50 (53) | 101 ± 171 | 95 ± 119 | ||
| >50 (57) | 112 ± 123 | .275 | 95 ± 101 | .862 |
| Sex | ||||
| M (68) | 102 ± 87 | 89 ± 58 | ||
| F (42) | 115 ± 212 | .107 | 104 ± 162 | .216 |
| WBC (×109/L) | ||||
| ≤50 (79) | 103 ± 153 | 85 ± 102 | ||
| >50 (29) | 121 ± 136 | .266 | 119 ± 130 | .079 |
| LDH | ||||
| ≥N, ≤5 × N (92) | 96 ± 142 | 84 ± 96 | ||
| >5 × N (14) | 188 ± 179 | .006* | 159 ± 175 | .038* |
| CD7 | ||||
| Negative (70) | 105 ± 115 | 87 ± 94 | ||
| Positive (17) | 188 ± 279 | .019* | 141 ± 193 | .121 |
| Chromosomal aberration | ||||
| − (42) | 97 ± 80 | 85 ± 53 | ||
| + (65) | 116 ± 180 | .398 | 100 ± 136 | .438 |
| − (42) | 97 ± 80 | 85 ± 53 | ||
| t(8;21) (13) | 113 ± 108 | .898 | 79 ± 60 | .677 |
| t(15;17) (17) | 51 ± 29 | .010* | 63 ± 52 | .045* |
| inv(16) (3) | 78 ± 21 | .891 | 89 ± 43 | .733 |
| 11q23 (3) | 81 ± 66 | >.999 | 77 ± 44 | >.999 |
| MAKA (6) | 300 ± 471 | .554 | 213 ± 317 | .513 |
| others (25) | 122 ± 148 | .866 | 112 ± 28 | .856 |
| Response to initial chemotherapy | ||||
| CR (68) | 97 ± 115 | 91 ± 96 | ||
| NR (32) | 144 ± 212 | .020* | 110 ± 147 | .597 |
Values are means ± SD. Analyzed by Mann-Whitney's U-test.
Abbreviation: MAKA, major karyotypic abnormalities.
P < .05.